Issuu

MAXIMIZING NUTRITIONAL SUPPORT ALONGSIDE

GLP-1 THERAPY

The Role of Chia Fiber and Protein

Support Health Throughout and Beyond Treatment

Emphasizing Nutrient Density

People seeking a healthier weight are increasingly turning to medications such as glucagon-like peptide-1 (GLP-1) receptor agonists, which were developed to influence insulin secretion, but can also suppress appetite.

Developed initially to manage type-2 diabetes, GLP-1s have also been FDA-approved for chronic weight management.

Challenges of GLP-1 Therapy

Nearly half of U.S. adults (41.9%), are living with obesity today.

GLP-1 medications such as Ozempic, Wegovy, and Mounjaro represent a significant advancement in weight management and glycemic control. Yet they present notable challenges that can lead to negative health consequences like reduced muscle and bone mass, as well as complicate treatment adherence. They also introduce a further consideration: how to get sufficient essential nutrients from much smaller meal volumes while maintaining health and long-term well-being once appetite returns.

Chia Fiber and Chia Protein can Help

These uniquely valuable tools that can help GLP-1 users maximize their nutritional density and effectively manage side effects. The result: More sustainable weight loss that supports whole-person health.

GLP-1 medications function in part by slowing gastric emptying and reducing appetite, resulting in significantly decreased food intake and potentially lower nutrient intake. While this mechanism drives weight loss, it creates a critical nutritional challenge: How to make every bite count by optimizing micro- and macronutrient density to preserve lean mass, support energy, and maintain metabolic health from a substantially reduced volume of food. Otherwise, users will risk losing a significant amount of lean muscle mass, which is essential for supporting metabolic function, physical strength, and long-term health outcomes.

The data on muscle loss during GLP-1 therapy is particularly concerning, with research showing that 25% to 40% of weight lost consists of lean muscle tissue. For a patient experiencing 50 pounds of weight loss, this could translate to 12 to 20 pounds of muscle loss.

Equally challenging, for many, are the gastrointestinal side effects associated with GLP-1 therapy. Nausea, diarrhea, and constipation affect a substantial proportion of users. While the mechanisms behind these effects are not fully understood, they likely involve altered gastric emptying, central nervous system effects, changes in nutrient absorption, and modified intestinal motility. These digestive symptoms can add to the challenge of consuming adequate nutrition. For some users, the symptoms may even cause them to quit taking GLP-1s altogether.

Keys to GLP-1 Support: Fiber and Protein

GLP-1 is an incretin hormone the body releases following food consumption. It promotes satiety, stimulates glucosedependent insulin secretion, slows gastric emptying, and helps regulate appetite through central mechanisms in the brain. GLP-1 medications are synthetic analogs that amplify these endogenous effects. What’s more, both fiber and protein naturally support the same physiological pathways involved in satiety and metabolism that GLP-1 medications target. That makes them ideal nutrients for addressing challenges relating to GLP-1 therapy.

Recent expert guidance on GLP-1 utilization has emphasized the importance of helping users:

choose nutrient-dense foods

maintain lean muscle mass

address the side effects that can lead to stopping treatment

optimize dietary approach, emphasizing lean proteins, whole grains, fruits and vegetables, and healthy fats

PROTEIN

• Mantain muscle mass

• Promote satiety

• Mantain weight loss

DIETARY FIBER

• Promote gastrointestinal (GO) health

• Promote satiety

• Maintain weight loss

High-protein meals demonstrate particular efficacy in enhancing GLP-1 secretion compared to low-protein alternatives. Protein intake alone is sufficient to trigger GLP-1 release, and specific peptides derived from protein digestion can inhibit the enzyme DPPIV, which normally degrades GLP-1. This means high-quality protein may help extend the beneficial effects of circulating GLP-1 while supporting lean muscle mass maintenance.

Dietary fiber operates through two distinct mechanisms. First, it exerts direct effects in the proximal intestine by activating specific receptors that trigger GLP-1 release. Second, when fiber reaches the colon, intestinal bacteria ferment it into shortchain fatty acids (SCFAs), which are natural GLP-1 stimulators. These dual functions mean fiber can promote GLP-1 release throughout the entire gastrointestinal tract, creating sustained impacts on satiety and glucose metabolism. That’s especially advantageous for patients attempting to maintain nutritional adequacy from reduced meal volumes.

Chia Ingredients for GLP-1

Supporting Nutrition

Not all fiber sources are equally tolerable when the digestive system is already managing the effects of slowed gastric emptying and altered gut motility. Many high-fiber foods or supplements can exacerbate bloating, gas, and discomfort, which is particularly problematic for GLP-1 users already experiencing nausea or constipation from their medication.

THE DIGESTIVE HEALTH BENEFIT OF CHIA FIBER

Chia fiber has unique properties that make it particularly well-suited for individuals undergoing GLP-1 therapy. It increases luminal viscosity, which contributes to enhanced satiety without causing significant digestive discomfort. Unlike some fibers that undergo rapid fermentation in the upper gastrointestinal tract (potentially causing gas and bloating), chia fiber ferments slowly and primarily in the colon. This slowand-steady fermentation profile contributes to high digestive tolerance and creates prebiotic effects that support friendly intestinal microbiota.

Clinical research across five trials has demonstrated that chia fiber supplementation promotes the growth of beneficial bacteria, including specific SCFA-producing species such as Enterococcus and Lactobacillus. These bacterial species produce the short-chain fatty acids that naturally stimulate endogenous GLP-1 production, potentially creating synergistic effects with GLP-1 medications. The increased bacterial diversity also positively impacts overall gastrointestinal health by increasing supportive metabolites, strengthening the intestinal barrier, and reducing inflammation — all factors that may help mitigate the gastrointestinal side effects of GLP-1 medications.

Chia’s unique gel-forming properties also enhance satiety without excess bulk or bloating. The soluble fiber in chia may help limit absorption of dietary fat, providing supplementary support for weight management.

Additionally, it’s slow, colon-targeted fermentation supports SCFA production and microbiome balance that can further stimulate endogenous GLP-1- release.

Large Intestine

Small Intestine

Stomach

THE MUSCLE-PRESERVING PROPERTIES OF CHIA PROTEIN

Adequate protein intake is essential for GLP-1 users to protect lean mass and support satiety. And use of GLP-1s should be combined with resistance training, experts recommend. But addressing muscle loss during weight reduction calls for more than just increasing protein intake and exercise. The quality of protein and its bioavailability are critically important, particularly when patients are eating smaller portions and feel less hungry.

These characteristics position chia protein as an excellent option for preserving lean muscle mass during weight loss, especially the rapid and significant weight loss that comes with taking a GLP-1. When users struggle to consume adequate protein due to reduced appetite, every gram ought to provide the maximum benefit. A protein source that offers high digestibility and amino acid balance delivers optimal muscle-building support in a smaller package, maximizing nutritional density. This combination thus helps meet protein goals even when appetite is low. And particularly in the weight maintenance phase, these attributes can assist in preventing rebound weight gain and supporting ongoing muscle health.

Chia protein provides a plant-based protein source with a complete amino acid profile, high digestibility, and good absorptionall high marks when it comes to protein quality. It provides a well-balanced amino acid profile, delivering the essential building blocks muscles require in the right proportions. Chia protein’s high digestibility helps ensure efficient absorption and utilization of constituent amino acids. Plus, it demonstrates fast-to-intermediate digestion rates, which supports effective muscle protein synthesis.

Practical Applications

Incorporating Chia into GLP-1 Treatment Plans

The utility of chia fiber and protein as nutritional tools lies in their versatility. They can be incorporated into smoothies, mixed into yogurt, added to oatmeal, or included in baked goods. For users managing early satiety and occasional nausea, having concentrated sources of fiber and protein that can be consumed in small volumes provides big practical advantages.

To be clear, these ingredients are food-based complements to GLP-1 therapy, not pharmaceutical interventions. They are not intended to replace prescribed medical treatment. Rather, they’re simple, relatively inexpensive food-based components that address the specific nutritional challenges faced by GLP-1 users. They facilitate meeting fiber requirements without digestive distress. They provide high-quality protein to support muscle preservation. And they may support the body’s endogenous GLP-1 pathways, functioning complementarily rather than antagonistically with medication regimens.

Chia fiber and protein can be incorporated into everyday recipes or formulations – from smoothies and baked goods to supplements – offering a clean-label, functional solution for the evolving GLP-1 consumer market.

Maintaining Results after GLP-1 Therapy

In the context of weight maintenance, when GLP-1 therapy is reduced or discontinued — whether at a physician’s direction or once weight goals are achieved, maintaining results becomes an important phase of care. Appetite often increases, and without nutritional strategies that promote satiety and help preserve lean muscle mass, weight regain may occur. Emphasizing nutrient-dense foods and functional ingredients such as chia protein and fiber can help support this transition by providing lasting fullness, balanced energy, and lean muscle protection for ongoing metabolic health.

THE BOTTOM LINE

While GLP-1 medications offer substantial therapeutic benefits, their long-term effects continue to be investigated. What we know for sure: Successful outcomes call for more than pharmaceutical intervention alone. They necessitate maintaining a consistent, balanced diet that supports muscle preservation, gastrointestinal health, and overall wellness.

For patients navigating reduced appetite, digestive challenges, and the imperative to maximize nutritional density in every calorie consumed, chia fiber and protein represent practical, evidencebased nutritional tools positioned to address these specific challenges. While they do not constitute comprehensive solutions, they offer targeted support in the areas where GLP-1 users face the greatest nutritional demands.

DISCLAIMER

This communication is intended for B2B use, and no statements are meant to be perceived as approved by regulatory authorities. Local regulations must be reviewed to confirm permissibility of ingredients and claims for each food category.

REFERENCES

Scan the QR code to access scientific references.

References

1. Baggio, L. L., & Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132:2131–2157. https://www.gastrojournal.org/action/ showPdf?pii=S0016-5085(07)00580-X PubMed+1

2. Tanday, N., Flatt, P. R., & Irwin, N. (2022). Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands. British Journal of Pharmacology, 179(4), 526-541. https://pmc.ncbi.nlm.nih.gov/articles/PMC7081944/pdf/nihms-1563249.pdf

3. Smith, N. K., Hackett, T. A., Galli, A., & Flynn, C. R. (2019). GLP-1: Molecular mechanisms and outcomes of a complex signalling system. Neurochemistry International, 128, 94-105. https://pmc.ncbi.nlm.nih.gov/articles/ PMC7081944/?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc

4. Gribble, F. M., & Reimann, F. (2017). Signalling in the gut endocrine axis. Physiology & Behavior. https://www.sciencedirect.com/science/article/abs/pii/ S0031938416311143

5. Van der Klaauw, A. A., Keogh, J. M., Henning, E., Trowse, V. M., Dhillo, W. S., Ghatei, M. A., & Farooqi, I. S. (2013). High protein intake stimulates postprandial GLP-1 and PYY release. Obesity (Silver Spring, Md.), 21(8), 1602-1607. https://pmc.ncbi.nlm. nih.gov/articles/PMC6548554/pdf/EMS83166.pdf

6. Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012). Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes, 61(2), 364–371. https://pmc.ncbi.nlm.nih.gov/articles/ PMC3266401/pdf/364.pdf

7. Meloni, A. R., DeYoung, M. B., Lowe, C., & Parkes, D. G. (2013). The role of glucagonlike peptide-1 in the regulation of lipid metabolism and body weight. Diabetes, Obesity & Metabolism, 15(—), —-—. https://pmc.ncbi.nlm.nih.gov/articles/PMC3556522/pdf/dom0015-0015.pdf

8. Cisternas, C., et al. (2024). Impact of dietary fiber fraction of chia seed on hepatic steatosis and metabolic disturbances induced by a high-fat diet in rodents. Journal of Functional Foods, 105, 105543. https://www.sciencedirect.com/science/article/ pii/S1756464624003311?ref=pdf_download&fr=RR-2&rr=9a3c6dde5f70f50e

9. Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017). Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes, Obesity & Metabolism, 19(3), 336–347. https://pubmed.ncbi.nlm.nih.gov/27860132/

10. Khushi Soni, Mr. Nadeem Chhipa, Dr. Pragnesh Patani, (2024). PHARMACOLOGICAL ACTIVITIES OF CHIA SEEDS A COMPREHENSIVE REVIEW. JTPCP, Vol. 31; 888-898 https://jptcp.com/index.php/jptcp/article/view/8804/8220

11. Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. (2024). Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. Nov;12(11):785-787. doi: 10.1016/ S2213-8587(24)00272-9.

12. Hope DCD, Tan TMM. (2024) Adaptive infusion of a glucagon-like peptide-1/ glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trialNat Rev Endocrinol.26:1479 –1491. https://dom-pubs.onlinelibrary.wiley.com/doi/pdf/10.1111/dom.15448

13. Almandoz JP, Wadden TA, Tewksbury C, et al. Obesity. (2024). Nutritional considerations with anti-obesity medications.Obesity (Silver Spring);32:1613–1631 https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24067

14. Ullah R, Nadeem M, Khalique A, Imran M, Mehmood S, Javid A, Hussain. J Food Sci Technol (2016) Nutritional and therapeutic perspectives of Chia (Salvia hispanica L.): a review. J Food Sci Technol (April 2016) 53(4):1750–1758. https://pmc.ncbi.nlm.nih.gov/articles/PMC4926888/pdf/13197_2015_ Article_1967.pdf

15. Dugardin C, Cudennec B, Tourret M, et al. Nutrients. (2020). Explorative Screening of Bioactivities Generated by Plant-Based Proteins after In Vitro Static Gastrointestinal Digestion. Nutrients, 12(12), 3746. https://www.mdpi.com/2072-6643/12/12/3746

16. Khalid W, et al. Food Sci Nutr. (2022). Chia seeds (Salvia hispanica L.): A therapeutic weapon in metabolic disorders. Food Sci Nutr. 2023;11:3–16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9834868/pdf/FSN3-11-3.pdf

17. Vuksan V, et al. Nutr Metab Cardiovasc Dis. (2017). Salba-chia (Salvia hispanica L.) in the treatment of overweight and obese patients with type 2 diabetes: A double-blind randomized controlled trial. Nutrition, Metabolism and Cardiovascular Diseases, Volume 0, Issue 0, 138 - 146. https://www.nmcd-journal.com/article/S0939-4753(16)30329-5/abstract

18. Tamargo A, Martin D, Navarro Del Hierro J, Moreno-Arribas MV, Muñoz LA. Food Res Int. (2020). Intake of soluble fibre from chia seed reduces bioaccessibility of lipids, cholesterol and glucose in the dynamic gastrointestinal model simgi®. Food Research International, Volume 137,109364,ISSN 0963-9969, https://doi.org/10.1016/j.foodres.2020.109364.

19. Juangco, JR, et al. (2021). Effectiveness of chia (Salvia hispanica L.) as an adjuvant therapy for Type 2 diabetes mellitus: A systematic review and meta-analysis. Health Sciences Journal, 11(2), 123-131

20. Mozaffarian, D, et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring);33:1475–1503. www.obesityjournal.org

Benexia®, a Leader in the Industry

Launched in 2000, Benexia® is a world leader in the production, processing, and commercialization of chia and chia-based ingredients. Our company is vertically integrated from agricultural production to final ingredients and solutions, including plant cultivation, extraction, concentration processes, and ingredients development.

We guarantee traceability from the fields and certified quality (GAP, GMP-HACCP, and FSSC 22000). Benexia products are certified Halal and Kosher.

Sustainability and Corporate Responsibility

Benexia employs regenerative agriculture to achieve lower carbon and water footprints from planting to harvesting. These practices are incorporated by the brand’s farming partners in Bolivia, Argentina, and Paraguay. Harvested chia seeds are processed without the use of gas or water. Seeds are cleaned and separated using physical processes such as airflow and density-based separation methods, yielding a final seed product that’s 99.95% pure.

Since its founding in 2005, Benexia is dedicated to supporting the welfare of its local communities. Benexia is aligned with the United Nations’ Sustainability Development Goals and is on track to complete its B Corp certification by 2025. Half of Benexia’s partner shareholders are chia farmers. This guarantees fair pricing and technical support within the company’s supply chain as well as full traceability of ingredients.

Our Team, the Best Customer Service

We’re passionate about health, wellbeing, and providing exceptional service for our customers. We offer support in formulation, nutrition, scientific and regulatory matters, with the best experts to assist your needs.